Erythropoiesis in Polycythemia Vera is Hyper-proliferative and Has Accelerated Maturation

Overview

Journal Blood Cells Mol Dis

Specialty Hematology

Date 2009 Mar 7

PMID 19264517

Citations 10

Authors

Hana Bruchova

Donghoon Yoon

Archana M Agarwal

Sabina Swierczek

Josef T Prchal

Affiliations

Soon will be listed here.

Abstract

Polycythemia vera (PV) is an acquired myeloproliferative clonal disorder, characterized by augmented erythropoiesis. To better define PV pathogenesis, we performed an in vitro erythroid expansion from peripheral blood mononuclear cells of controls and PV patients and evaluated the cells for proliferation, apoptosis, erythroid differentiation, and morphology at the defined time points. PV erythroid progenitors exhibited increased proliferation at days 9-14 and accelerated maturation at days 7-14, with a larger S-phase population (40%) than controls (20%) at day 11; however, the proportion of apoptotic cells was comparable to controls. Previously, we have identified PV-specific dysregulation of several microRNAs (i.e. miR-150, 451, 222, 155, 378). We had analyzed expression profiles of selected target genes of these microRNAs based on in silico prediction and their known function pertinent to the observed PV-specific erythropoiesis differences. p27, cMYB and EPOR showed differential expression in PV erythroid progenitors at the specific stages of erythroid differentiation. In this study, we identified accelerated maturation and hyper-proliferation at early stages of PV erythropoiesis. We speculate that aberrant expression of p27, c-MYB, and EPOR may contribute to these abnormal features in PV erythropoiesis.

Citing Articles

Expression of CD markers in JAK2 positive myeloproliferative neoplasms: Prognostic significance.

Shahrabi S, Ehsanpour A, Heidary S, Shahjahani M, Maleki Behzad M Oncol Rev. 2018; 12(2):373.

PMID: 30405895 PMC: 6199554. DOI: 10.4081/oncol.2018.373.

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.

Tashi T, Swierczek S, Kim S, Salama M, Song J, Heikal N Leukemia. 2018; 32(8):1830-1833.

PMID: 29556018 PMC: 6552660. DOI: 10.1038/s41375-018-0080-6.

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells.

Wolf A, Eulenfeld R, Gabler K, Rolvering C, Haan S, Behrmann I JAKSTAT. 2013; 2(3):e24574.

PMID: 24069558 PMC: 3772110. DOI: 10.4161/jkst.24574.

Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera.

Hricik T, Federici G, Zeuner A, Alimena G, Tafuri A, Tirelli V Am J Hematol. 2013; 88(9):723-9.

PMID: 23720412 PMC: 3771389. DOI: 10.1002/ajh.23487.

Implication of microRNAs in the pathogenesis of MDS.

Fang J, Varney M, Starczynowski D Curr Pharm Des. 2012; 18(22):3170-9.

PMID: 22571695 PMC: 4863958. DOI: 10.2174/1381612811209023170.

References

Vegiopoulos A, Garcia P, Emambokus N, Frampton J . Coordination of erythropoiesis by the transcription factor c-Myb. Blood. 2006; 107(12):4703-10. PMC: 1895806. DOI: 10.1182/blood-2005-07-2968. View

Xiao C, Calado D, Galler G, Thai T, Patterson H, Wang J . MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007; 131(1):146-59. DOI: 10.1016/j.cell.2007.07.021. View

Yoon D, Watowich S . Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway. Exp Hematol. 2003; 31(12):1310-6. PMC: 2388246. DOI: 10.1016/j.exphem.2003.08.009. View

Prchal J, AXELRAD A . Letter: Bone-marrow responses in polycythemia vera. N Engl J Med. 1974; 290(24):1382. DOI: 10.1056/nejm197406132902419. View

Lin H, Sternfeld D, Shinpock S, Popp R, Mucenski M . Functional analysis of the c-myb proto-oncogene. Curr Top Microbiol Immunol. 1996; 211:79-87. DOI: 10.1007/978-3-642-85232-9_8. View

Wang Q, Huang Z, Xue H, Jin C, Ju X, Han J . MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood. 2007; 111(2):588-95. DOI: 10.1182/blood-2007-05-092718. View

Zhang J, Socolovsky M, Gross A, Lodish H . Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood. 2003; 102(12):3938-46. DOI: 10.1182/blood-2003-05-1479. View

James C . The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?. Hematology Am Soc Hematol Educ Program. 2008; :69-75. DOI: 10.1182/asheducation-2008.1.69. View

Bruchova H, Yoon D, Agarwal A, Mendell J, Prchal J . Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007; 35(11):1657-67. PMC: 2699372. DOI: 10.1016/j.exphem.2007.08.021. View

10.

Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F . MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102(50):18081-6. PMC: 1312381. DOI: 10.1073/pnas.0506216102. View

11.

Simon M . Transcription factor GATA-1 and erythroid development. Proc Soc Exp Biol Med. 1993; 202(2):115-21. DOI: 10.3181/00379727-202-43519a. View

12.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

13.

Kralovics R, Teo S, Li S, Theocharides A, Buser A, Tichelli A . Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006; 108(4):1377-80. DOI: 10.1182/blood-2005-11-009605. View

14.

Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F . The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007; 110(3):1013-21. DOI: 10.1182/blood-2006-10-054940. View

15.

Levine R, Gilliland D . Myeloproliferative disorders. Blood. 2008; 112(6):2190-8. PMC: 2962533. DOI: 10.1182/blood-2008-03-077966. View

16.

Gaikwad A, Verstovsek S, Yoon D, Chang K, Manshouri T, Nussenzveig R . Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007; 35(6):931-8. DOI: 10.1016/j.exphem.2007.03.012. View

17.

Socolovsky M, Nam H, Fleming M, Haase V, Brugnara C, Lodish H . Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001; 98(12):3261-73. DOI: 10.1182/blood.v98.12.3261. View

18.

Adamson J, Fialkow P, Murphy S, Prchal J, Steinmann L . Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976; 295(17):913-6. DOI: 10.1056/NEJM197610212951702. View

19.

Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N . Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004; 32(2):179-87. DOI: 10.1016/j.exphem.2003.11.003. View

20.

Neildez-Nguyen T, Wajcman H, Marden M, Bensidhoum M, Moncollin V, Giarratana M . Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol. 2002; 20(5):467-72. DOI: 10.1038/nbt0502-467. View